FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Baptist Gallwitz

Research Profile

Chemicals & Drugs

Disorders

Co-author Network

Publications

TOP 3
Burkhard Göke; Åsa Hellqvist; Johan G Eriksson; Baptist Gallwitz; Ingrid Gause-Nilsson
Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
Baptist Gallwitz
Novel oral anti-obesity agents: new perspectives with lorcaserin?
Baptist Gallwitz; J Rosenstock; Maximilian von Eynatten; A Emser; Hans-Juergen Woerle
Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Baptist Gallwitz (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Burkhard Göke; Åsa Hellqvist; Johan G Eriksson; Baptist Gallwitz; Ingrid Gause-Nilsson
Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial.
International journal of clinical practice 2013;67(4):307-16.
2013: Baptist Gallwitz
Novel oral anti-obesity agents: new perspectives with lorcaserin?
Drugs 2013;73(5):393-5.
2013: Baptist Gallwitz; J Rosenstock; Maximilian von Eynatten; A Emser; Hans-Juergen Woerle
Linagliptin is more effective than glimepiride at achieving a composite outcome of target HbA₁c < 7% with no hypoglycaemia and no weight gain over 2 years.
International journal of clinical practice 2013;67(4):317-21.
2013: Baptist Gallwitz; Christof Kazda; Petra Kraus; Claudia Nicolay; Guntram Schernthaner
Contribution of insulin deficiency and insulin resistance to the development of type 2 diabetes: nature of early stage diabetes.
Acta diabetologica 2013;50(1):39-45.
2013: Baptist Gallwitz; Julio Rosenstock; Hans-Juergen Woerle
Preregistration of study design and non-inferiority margin - Authors' reply.
Lancet 2013;381(9861):115-6.
2013: Baptist Gallwitz
Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes.
Diabetes, metabolic syndrome and obesity : targets and therapy 2013;6():1-9.
2013: Thomas Leyhe; Anna-Laura Säuberlich; Ralf Saur; Johannes Bretscher; Thomas Ethofer; Andreas Fallgatter; Baptist Gallwitz; Hans-Ulrich Häring; Reinhild Klein; Stefan Klingberg; Andreas Künle; Karsten Müssig
Low performance in attention testing is associated with reduced grey matter density of the left inferior frontal gyrus in euthyroid patients with Hashimoto's thyroiditis.
Brain, behavior, and immunity 2013;27(1):33-7.
2012: Baptist Gallwitz; Sanjay Patel; Thomas Rauch; Julio Rosenstock; Maximilian von Eynatten; Sudipta Bhattacharya; Klaus A Dugi; Hans-Juergen Woerle
2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial.
Lancet 2012;380(9840):475-83.
2012: Baptist Gallwitz; Bruno Guerci; Juan Guzman; Jacek Kiljański; Hélène Sapin; Bruce R Basson; Francesco Dotta; Andreas Festa; Rafael Simó; Michael Trautmann; Guntram Schernthaner
Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial.
Lancet 2012;379(9833):2270-8.
2012: Monika Milian; Baptist Gallwitz; Jürgen Honegger; Guenter Schnauder; Philipp Teufel; Tsambika Psaras
The development of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25). Part II: normative data from 1784 healthy people.
Clinical endocrinology 2012;76(6):861-7.
2012: Monika Milian; Baptist Gallwitz; Jürgen Honegger; Guenter Schnauder; Philipp Teufel; Tsambika Psaras
The development of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25). Part I: construction and psychometric properties.
Clinical endocrinology 2012;76(6):851-60.
2012: Karsten Müssig; Anna-Laura Säuberlich; Ralf Saur; Claudia Weinert; Thomas Ethofer; Baptist Gallwitz; Hans-Ulrich Häring; Reinhild Klein; Stefan Klingberg; Andreas Künle; Thomas Leyhe
Thyroid peroxidase antibody positivity is associated with symptomatic distress in patients with Hashimoto's thyroiditis.
Brain, behavior, and immunity 2012;26(4):559-63.
2012: Baptist Gallwitz
Linagliptin-a novel dipeptidyl peptidase inhibitor for type 2 diabetes therapy.
Clinical medicine insights. Endocrinology and diabetes 2012;5():1-11.
2012: Baptist Gallwitz
Anorexigenic effects of GLP-1 and its analogues.
Handbook of experimental pharmacology 2012;(209):185-207.
2011: Baptist Gallwitz
Glucagon-like peptide-1 analogues for Type 2 diabetes mellitus: current and emerging agents.
Drugs 2011;71(13):1675-88.
2011: Baptist Gallwitz
Small molecule dipeptidylpeptidase IV inhibitors under investigation for diabetes mellitus therapy.
Expert opinion on investigational drugs 2011;20(6):723-32.
2011: Tsambika Psaras; Jürgen Honegger; Baptist Gallwitz; M Milian
Are there gender-specific differences concerning quality of life in treated acromegalic patients?
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2011;119(5):300-5.
2011: Baptist Gallwitz; Michael Böhmer; Thomas Segiet; Andrea Mölle; Karsten Milek; Bernd Becker; Karin Helsberg; Helmut Petto; Natalie Peters; Oliver Bachmann
Exenatide twice daily versus premixed insulin aspart 70/30 in metformin-treated patients with type 2 diabetes: a randomized 26-week study on glycemic control and hypoglycemia.
Diabetes care 2011;34(3):604-6.
2011: Karsten Müssig; Britta Besemer; Ralf Saur; Stefan Klingberg; Hans-Ulrich Häring; Baptist Gallwitz; Thomas Leyhe
Deteriorated executive functions in patients with successful surgery for pituitary adenomas compared with other chronically ill patients.
Journal of the International Neuropsychological Society : JINS 2011;17(2):369-75.
2011: Itamar Raz; Baptist Gallwitz
The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue.
The review of diabetic studies : RDS 2011;8(3):288-92.
2011: Baptist Gallwitz
GLP-1 agonists and dipeptidyl-peptidase IV inhibitors.
Handbook of experimental pharmacology 2011;(203):53-74.
2011: Tsambika Psaras; M Milian; V Hattermann; T Freiman; Baptist Gallwitz; Jürgen Honegger
Demographic factors and the presence of comorbidities do not promote early detection of Cushing's disease and acromegaly.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2011;119(1):21-5.
2010: Baptist Gallwitz
[Modern diabetes management. DPP-4 inhibitors have been established as progress (interview by Christine Vetter)].
MMW Fortschritte der Medizin 2010;152(25-27):40-1.
2010: Karsten Müssig; M O Oksüz; K Dudziak; B Ueberberg; Manfred Wehrmann; Marius Horger; S Schulz; Hans-Ulrich Häring; Christina Pfannenberg; Roland Bares; Baptist Gallwitz; Stephan Petersenn
Association of somatostatin receptor 2 immunohistochemical expression with [111In]-DTPA octreotide scintigraphy and [68Ga]-DOTATOC PET/CT in neuroendocrine tumors.
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme 2010;42(8):599-606.
2010: Baptist Gallwitz
The evolving place of incretin-based therapies in type 2 diabetes.
Pediatric nephrology (Berlin, Germany) 2010;25(7):1207-17.
2010: Baptist Gallwitz
[Diabetes therapy--novel drugs to come (DPP-4 inhibitors, GLP-1 agonists, SGLT-2 inhibitors)].
MMW Fortschritte der Medizin 2010;152(20):43-4.
2010: Baptist Gallwitz
[Incretins: do they exert cardiovascular effects?].
Herz 2010;35(3):130-8.
2010: Baptist Gallwitz
[DPP-4 inhibitors in clinical use. Therapy without the risk of hypoglycaemia].
Pharmazie in unserer Zeit 2010;39(2):114-8.
2010: Henning Blume; Ralph-Steven Wedemeyer; Baptist Gallwitz
[Importance of GLP-1 for glucose homeostasis. Discovery of incretin].
Pharmazie in unserer Zeit 2010;39(2):100-6.
2010: Baptist Gallwitz
Benefit-risk assessment of exenatide in the therapy of type 2 diabetes mellitus.
Drug safety : an international journal of medical toxicology and drug experience 2010;33(2):87-100.
2010: Tsambika Psaras; Monika Milian; Valerie Hattermann; Baptist Gallwitz; Thomas Freiman; Jürgen Honegger
Aftercare in patients with Cushing's disease and acromegaly: is there room for improvement?
Acta neurochirurgica 2010;152(2):271-8.
2010: Baptist Gallwitz
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin.
Diabetes, metabolic syndrome and obesity : targets and therapy 2010;3():117-24.
2010: Baptist Gallwitz; A Vaag; A Falahati; S Madsbad
Adding liraglutide to oral antidiabetic drug therapy: onset of treatment effects over time.
International journal of clinical practice 2010;64(2):267-76.
2010: Baptist Gallwitz; Hans-Ulrich Häring
Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas.
Diabetes, obesity & metabolism 2010;12(1):1-11.
2009: Carsten Henninger; Michael Kramer; Marius Horger; Andreas Fritsche; Baptist Gallwitz; Karsten Müssig
[Ileus of uncommon cause--important and weighty facts].
Deutsche medizinische Wochenschrift (1946) 2009;134(51-52):2640.
2009: Karsten Müssig; Harald Staiger; Fausto Machicao; Jürgen Machann; Fritz Schick; Silke A Schäfer; Claus D Claussen; Jens J Holst; Baptist Gallwitz; Norbert Stefan; Andreas Fritsche; Hans-Ulrich Häring
Preliminary report: genetic variation within the GPBAR1 gene is not associated with metabolic traits in white subjects at an increased risk for type 2 diabetes mellitus.
Metabolism: clinical and experimental 2009;58(12):1809-11.
2009: Baptist Gallwitz
Implications of postprandial glucose and weight control in people with type 2 diabetes: understanding and implementing the International Diabetes Federation guidelines.
Diabetes care 2009;32 Suppl 2():S322-5.
2009: Michael A Nauck; Tina Vilsbøll; Baptist Gallwitz; Alan Garber; Sten Madsbad
Incretin-based therapies: viewpoints on the way to consensus.
Diabetes care 2009;32 Suppl 2():S223-31.
2009: Karsten Müssig; Thomas Leyhe; Britta Besemer; Ralf Saur; Hans-Ulrich Häring; Baptist Gallwitz; Stefan Klingberg
Younger age is a good predictor of better executive function after surgery for pituitary adenoma in adults.
Journal of the International Neuropsychological Society : JINS 2009;15(5):803-6.
2009: Karsten Müssig; Thomas Leyhe; Sonja Holzmüller; Reinhild Klein; Claudia Weinert; Ralf Saur; Stefan Klingberg; Hans-Ulrich Häring; Baptist Gallwitz
Increased prevalence of antibodies to central nervous system tissue and gangliosides in Hashimoto's thyroiditis compared to other thyroid illnesses.
Psychoneuroendocrinology 2009;34(8):1252-6.
2009: Nancy A Thornberry; Baptist Gallwitz
Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).
Best practice & research. Clinical endocrinology & metabolism 2009;23(4):479-86.
2009: Thomas Leyhe; Mirjam Hügle; Baptist Gallwitz; Ralf Saur; Gerhard W Eschweiler
Increased occurrence of severe episodes in elderly depressed patients with elevated anti-thyroid antibody levels.
International journal of geriatric psychiatry 2009;24(7):779-81.
2009: Karsten Müssig; Harald Staiger; Fausto Machicao; Kerstin Kirchhoff; Martina Guthoff; Silke A Schäfer; Konstantinos Kantartzis; Günther Silbernagel; Norbert Stefan; Jens J Holst; Baptist Gallwitz; Hans-Ulrich Häring; Andreas Fritsche
Association of type 2 diabetes candidate polymorphisms in KCNQ1 with incretin and insulin secretion.
Diabetes 2009;58(7):1715-20.
2009: Silke A Schäfer; K Müssig; Harald Staiger; Fausto Machicao; Norbert Stefan; Baptist Gallwitz; Hans-Ulrich Häring; Andreas Fritsche
A common genetic variant in WFS1 determines impaired glucagon-like peptide-1-induced insulin secretion.
Diabetologia 2009;52(6):1075-82.
2009: Michael Haap; Baptist Gallwitz; Richard Meyermann; Michel Mittelbronn
Cushing's disease associated with both pituitary microadenoma and corticotroph hyperplasia.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2009;117(6):289-93.
2009: Baptist Gallwitz
[The value of incretin based therapies].
Deutsche medizinische Wochenschrift (1946) 2009;134(20):1062-6.
2009: Axel Haupt; Martina Guthoff; Silke A Schäfer; Kerstin Kirchhoff; Fausto Machicao; Baptist Gallwitz; Harald Staiger; Norbert Stefan; Andreas Fritsche; Hans-Ulrich Häring
The inhibitory effect of recent type 2 diabetes risk loci on insulin secretion is modulated by insulin sensitivity.
The Journal of clinical endocrinology and metabolism 2009;94(5):1775-80.
2009: Axel Haupt; Harald Staiger; Silke A Schäfer; K Kirchhoff; M Guthoff; Fausto Machicao; Baptist Gallwitz; Norbert Stefan; Hans-Ulrich Häring; Andreas Fritsche
The risk allele load accelerates the age-dependent decline in beta cell function.
Diabetologia 2009;52(3):457-62.
2009: Baptist Gallwitz
Preclinical and Clinical Data on Extraglycemic Effects of GLP-1 Receptor Agonists.
The review of diabetic studies : RDS 2009;6(4):247-59.
2009: Peter Weyrich; Harald Staiger; Alena Stancáková; Silke A Schäfer; Kerstin Kirchhoff; Susanne Ullrich; Felicia Ranta; Baptist Gallwitz; Norbert Stefan; Fausto Machicao; Johanna Kuusisto; Markku Laakso; Andreas Fritsche; Hans-Ulrich Häring
Common polymorphisms within the NR4A3 locus, encoding the orphan nuclear receptor Nor-1, are associated with enhanced beta-cell function in non-diabetic subjects.
BMC medical genetics 2009;10():77.
2008: Baptist Gallwitz
Saxagliptin, a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
IDrugs : the investigational drugs journal 2008;11(12):906-17.
2008: Thomas Leyhe; Karsten Müssig; Claudia Weinert; Christoph Laske; Hans-Ulrich Häring; Ralf Saur; Stefan Klingberg; Baptist Gallwitz
Increased occurrence of weaknesses in attention testing in patients with Hashimoto's thyroiditis compared to patients with other thyroid illnesses.
Psychoneuroendocrinology 2008;33(10):1432-6.
2008: Karsten Müssig; Manfred Wehrmann; Marius Horger; Roland Bares; Hans-Ulrich Häring; Baptist Gallwitz; S Petersenn
Lymph node gastrinoma in multiple endocrine neoplasia type 1 - a diagnostic challenge.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2008;116(9):554-7.
2008: Axel Haupt; Martina Guthoff; Baptist Gallwitz; Hans-Ulrich Haring; Andreas Fritsche
Variation in the CDKAL1 gene is associated with the titer of antibodies to GAD.
Diabetes care 2008;31(9):e66.
2008: Karsten Müssig; Thomas Remer; Axel Haupt; Baptist Gallwitz; Andreas Fritsche; Hans-Ulrich Häring; Christiane Maser-Gluth
11beta-hydroxysteroid dehydrogenase 2 activity is elevated in severe obesity and negatively associated with insulin sensitivity.
Obesity (Silver Spring, Md.) 2008;16(6):1256-60.
2008: Anne Dornhorst; HJ Lüddeke; Marek Honka; Ralf W Ackermann; Markus Meriläinen; Baptist Gallwitz; S Sreenan
Safety and efficacy of insulin detemir basal-bolus therapy in type 1 diabetes patients: 14-week data from the European cohort of the PREDICTIVE study.
Current medical research and opinion 2008;24(2):369-76.
2007: Silke A Schäfer; Otto Tschritter; Fausto Machicao; Claus Thamer; Norbert Stefan; Baptist Gallwitz; J J Holst; J M Dekker; L M 't Hart; L M t'Hart; G Nijpels; Timon W van Haeften; Hans-Ulrich Häring; Andreas Fritsche
Impaired glucagon-like peptide-1-induced insulin secretion in carriers of transcription factor 7-like 2 (TCF7L2) gene polymorphisms.
Diabetologia 2007;50(12):2443-50.
2007: Baptist Gallwitz
Sitagliptin: profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes (update).
Drugs of today (Barcelona, Spain : 1998) 2007;43(11):801-14.
2007: Karsten Müssig; Christina Schraml; Baptist Gallwitz; Claus D Claussen; Hans-Ulrich Häring; Fritz Schick; Bernd M Balletshofer
A novel MR-imaging technique using arterial spin labeling for thyroid gland perfusion in thyrotoxicosis.
Thyroid : official journal of the American Thyroid Association 2007;17(11):1155-6.
2007: Baptist Gallwitz
Sitagliptin with metformin: profile of a combination for the treatment of type 2 diabetes.
Drugs of today (Barcelona, Spain : 1998) 2007;43(10):681-9.
2007: Michael Haap; Baptist Gallwitz; Claus Thamer; Karsten Müssig; Hans-Ulrich Häring; Lothar Kanz; Jörg Thomas Hartmann
Symptomatic hypoglycemia during imatinib mesylate in a non-diabetic female patient with gastrointestinal stromal tumor.
Journal of endocrinological investigation 2007;30(8):688-92.
2007: Karsten Müssig; Stephan Petersenn; Manfred Wehrmann; Marius Horger; Peter Vierling; Hans-Ulrich Häring; Baptist Gallwitz
Somatostatin receptor expression in a parathyroid hormone-related peptide-secreting pancreatic neuroendocrine tumour causing severe hypercalcaemia.
European journal of gastroenterology & hepatology 2007;19(8):719-23.
2007: Karsten Müssig; Baptist Gallwitz; Jürgen Honegger; C J Strasburger; Martin Bidlingmaier; Fausto Machicao; A Bornemann; M B Ranke; Hans-Ulrich Häring; Stephan Petersenn
Pegvisomant treatment in gigantism caused by a growth hormone-secreting giant pituitary adenoma.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2007;115(3):198-202.
2007: Baptist Gallwitz
Review of sitagliptin phosphate: a novel treatment for type 2 diabetes.
Vascular health and risk management 2007;3(2):203-10.
2007: Baptist Gallwitz
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes.
Drugs of today (Barcelona, Spain : 1998) 2007;43(1):13-25.
2006: Baptist Gallwitz
Exenatide in type 2 diabetes: treatment effects in clinical studies and animal study data.
International journal of clinical practice 2006;60(12):1654-61.
2006: Karsten Müssig; Baptist Gallwitz
[Primary adrenal cortical insufficiency (Addison's disease)].
Deutsche medizinische Wochenschrift (1946) 2006;131(47):2655-6.
2006: Karsten Müssig; Baptist Gallwitz; M B Ranke; Marius Horger; Hans-Ulrich Häring; H J Quabbe
Acromegaly and end-stage renal disease: a diagnostic challenge.
Journal of endocrinological investigation 2006;29(8):745-9.
2006: Karsten Müssig; Baptist Gallwitz
[Lipohypertrophy].
Deutsche medizinische Wochenschrift (1946) 2006;131(33):1807-8.
2006: Baptist Gallwitz; H Lehnert; H Dittmann; Jürgen Honegger; R Teichmann; M Tatagiba; H U Häring
[Clinical pathways in endocrinology and diabetology].
Der Internist 2006;47(7):707-10, 711-2.
2006: Karsten Müssig; Baptist Gallwitz
[Erythema nodosum].
Deutsche medizinische Wochenschrift (1946) 2006;131(22):1267-8.
2006: Karsten Müssig; Claus Thamer; Roland Bares; Hans-Peter Lipp; Hans-Ulrich Häring; Baptist Gallwitz
Iodine-induced thyrotoxicosis after ingestion of kelp-containing tea.
Journal of general internal medicine 2006;21(6):C11-4.
2006: Baptist Gallwitz
Therapies for the treatment of type 2 diabetes mellitus based on incretin action.
Minerva endocrinologica 2006;31(2):133-47.
2006: Juris J Meier; Arnica Gethmann; Michael A Nauck; Oliver Götze; Frank Schmitz; Carolyn F Deacon; Baptist Gallwitz; Wolfgang E Schmidt; Jens J Holst
The glucagon-like peptide-1 metabolite GLP-1-(9-36) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans.
American journal of physiology. Endocrinology and metabolism 2006;290(6):E1118-23.
2006: Karsten Müssig; Simone Kaltenbach; Christiane Maser-Gluth; Michaela F Hartmann; Stefan A Wudy; Marius Horger; Baptist Gallwitz; Friedhelm Raue; Hans-Ulrich Häring; E Schulze
Late diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2006;114(4):208-14.
2006: Juris J Meier; Michael A Nauck; Bartholomaeus Kask; Jens J Holst; Carolyn F Deacon; Wolfgang E Schmidt; Baptist Gallwitz
Influence of gastric inhibitory polypeptide on pentagastrin-stimulated gastric acid secretion in patients with type 2 diabetes and healthy controls.
World journal of gastroenterology : WJG 2006;12(12):1874-80.
2006: Juris J Meier; Arnica Gethmann; O Götze; Baptist Gallwitz; Jens Juul Holst; Wolfgang E Schmidt; Michael A Nauck
Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans.
Diabetologia 2006;49(3):452-8.
2006: Karsten Müssig; Baptist Gallwitz; Fausto Machicao; Marius Horger; Hans-Ulrich Häring; E Kaiserling
Paraadrenal Castleman disease presenting with adrenal hyperandrogenism.
Journal of endocrinological investigation 2006;29(2):172-6.
2006: Baptist Gallwitz
The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions.
The review of diabetic studies : RDS 2006;3(4):208-16.
2006: Juris J Meier; Michael A Nauck; Andrea Pott; Kai Heinze; Oliver Goetze; Kerem Bulut; Wolfgang E Schmidt; Baptist Gallwitz; Jens J Holst
Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans.
Gastroenterology 2006;130(1):44-54.
2005: Juris J Meier; Baptist Gallwitz; M Askenas; K Vollmer; Carolyn F Deacon; Jens Juul Holst; Wolfgang E Schmidt; Michael A Nauck
Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes.
Diabetologia 2005;48(9):1872-81.
2005: Karsten Müssig; Marius Horger; Hans-Ulrich Häring; Baptist Gallwitz
Pheochromocytoma in a patient with sickle-beta-thalassemia.
The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians 2005;18(2):145-6.
2005: Baptist Gallwitz
Glucagon-like peptide-1 as a treatment option for type 2 diabetes and its role in restoring beta-cell mass.
Diabetes technology & therapeutics 2005;7(4):651-7.
2005: Karsten Müssig; Simone Kaltenbach; Fausto Machicao; Christiane Maser-Gluth; Michaela F Hartmann; Stefan A Wudy; Günter Schnauder; Hans-Ulrich Häring; Fritz J Seif; Baptist Gallwitz
17alpha-hydroxylase/17,20-lyase deficiency caused by a novel homozygous mutation (Y27Stop) in the cytochrome CYP17 gene.
The Journal of clinical endocrinology and metabolism 2005;90(7):4362-5.
2005: Karsten Müssig; Mathias Bartels; Baptist Gallwitz; Dirk Leube; Hans-Ulrich Häring; Tilo Kircher
Hashimoto's encephalopathy presenting with bipolar affective disorder.
Bipolar disorders 2005;7(3):292-7.
2005: Baptist Gallwitz
New therapeutic strategies for the treatment of type 2 diabetes mellitus based on incretins.
The review of diabetic studies : RDS 2005;2(2):61-9.
2005: Baptist Gallwitz
Glucagon-like peptide-1-based therapies for the treatment of type 2 diabetes mellitus.
Treatments in endocrinology 2005;4(6):361-70.
2004: Juris J Meier; Baptist Gallwitz; Bartholomaeus Kask; Carolyn F Deacon; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Stimulation of insulin secretion by intravenous bolus injection and continuous infusion of gastric inhibitory polypeptide in patients with type 2 diabetes and healthy control subjects.
Diabetes 2004;53 Suppl 3():S220-4.
2004: Michael A Nauck; Andrea El-Ouaghlidi; Bartholomäus Gabrys; Katrin Hücking; Jens J Holst; Carolyn F Deacon; Baptist Gallwitz; Wolfgang E Schmidt; Juris J Meier
Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
Regulatory peptides 2004;122(3):209-17.
2004: A Clemens; E Siegel; Baptist Gallwitz
Global risk management in type 2 diabetes: blood glucose, blood pressure, and lipids--update on the background of the current guidelines.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 2004;112(9):493-503.
2004: Kerem Bulut; Juris J Meier; Nikolaus Ansorge; Peter Felderbauer; Frank Schmitz; Peter Hoffmann; Wolfgang E Schmidt; Baptist Gallwitz
Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF--beta-mediated effect.
Regulatory peptides 2004;121(1-3):137-43.
2004: Karsten Müssig; Baptist Gallwitz; Hans-Ulrich Häring; Fritz J Seif
Manifestation of thyroid autoimmunity in patients successfully treated for hypercortisolism.
Clinical endocrinology 2004;61(2):284.
2004: Baptist Gallwitz
[Primary prevention of diabetes mellitus type 2].
Der Internist 2004;45 Suppl 1():S15-22.
2004: Michael A Nauck; Jörg Walberg; Arndt Vethacke; Andrea El-Ouaghlidi; Metin Senkal; Jens J Holst; Baptist Gallwitz; J Baptist Gallwitz; Wolfgang E Schmidt; Wolff Schmiegel
Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1.
Regulatory peptides 2004;118(1-2):89-97.
2004: Juris J Meier; Oliver Goetze; Jens Anstipp; Dirk Hagemann; Jens J Holst; Wolfgang E Schmidt; Baptist Gallwitz; Michael A Nauck
Gastric inhibitory polypeptide does not inhibit gastric emptying in humans.
American journal of physiology. Endocrinology and metabolism 2004;286(4):E621-5.
2004: Juris J Meier; Dirk Weyhe; Mark Michaely; Metin Senkal; Volker Zumtobel; Michael A Nauck; Jens J Holst; Wolfgang E Schmidt; Baptist Gallwitz
Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes.
Critical care medicine 2004;32(3):848-51.
2004: Juris J Meier; Michael A Nauck; Daniel Kranz; Jens J Holst; Carolyn F Deacon; Dirk Gaeckler; Wolfgang E Schmidt; Baptist Gallwitz
Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects.
Diabetes 2004;53(3):654-62.
2004: Baptist Gallwitz
[A new long-acting insulin analog. "Fewer hypoglycemias observed"].
MMW Fortschritte der Medizin 2004;146(3-4):47.
2003: Juris J Meier; Michael A Nauck; Nina Siepmann; Michael Greulich; Jens J Holst; Carolyn F Deacon; Wolfgang E Schmidt; Baptist Gallwitz
Similar insulin secretory response to a gastric inhibitory polypeptide bolus injection at euglycemia in first-degree relatives of patients with type 2 diabetes and control subjects.
Metabolism: clinical and experimental 2003;52(12):1579-85.
2003: Dirk Hagemann; Juris J Meier; Baptist Gallwitz; Wolfgang E Schmidt
[Appetite regulation by ghrelin - a novel neuro-endocrine gastric peptide hormone in the gut-brain-axis].
Zeitschrift für Gastroenterologie 2003;41(9):929-36.
2003: Andreas Clemens; Baptist Gallwitz
[Normalization of blood pressure and lipids in patients with diabetes].
Medizinische Klinik (Munich, Germany : 1983) 2003;98(7):368-76.
2003: Juris J Meier; Baptist Gallwitz; Stefan Salmen; Oliver Goetze; Jens J Holst; Wolfgang E Schmidt; Michael A Nauck
Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes.
The Journal of clinical endocrinology and metabolism 2003;88(6):2719-25.
2003: Juris J Meier; Baptist Gallwitz; Nina Siepmann; Jens Juul Holst; Carolyn F Deacon; Wolfgang E Schmidt; Michael A Nauck
Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia.
Diabetologia 2003;46(6):798-801.
2003: Juris J Meier; Baptist Gallwitz; Nina Siepmann; Jens J Holst; Carolyn F Deacon; Wolfgang E Schmidt; Michael A Nauck
The reduction in hepatic insulin clearance after oral glucose is not mediated by gastric inhibitory polypeptide (GIP).
Regulatory peptides 2003;113(1-3):95-100.
2003: Juris J Meier; Baptist Gallwitz; Michael A Nauck
Glucagon-like peptide 1 and gastric inhibitory polypeptide: potential applications in type 2 diabetes mellitus.
BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy 2003;17(2):93-102.
2002: Juris J Meier; Baptist Gallwitz; Wolfgang E Schmidt; Michael A Nauck
Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes.
Lancet 2002;360(9328):257.
2002: Juris J Meier; Michael A Nauck; Wolfgang E Schmidt; Baptist Gallwitz
Gastric inhibitory polypeptide: the neglected incretin revisited.
Regulatory peptides 2002;107(1-3):1-13.
2002: Juris J Meier; Silvia Deifuss; Baptist Gallwitz; Andreas Klamann; Wolff Schmiegel; Michael A Nauck
[Influence of impaired glucose tolerance on long-term survival after acute myocardial infarction].
Deutsche medizinische Wochenschrift (1946) 2002;127(21):1123-9.
2002: Juris J Meier; Baptist Gallwitz; Wolfgang E Schmidt; Michael A Nauck
Glucagon-like peptide 1 as a regulator of food intake and body weight: therapeutic perspectives.
European journal of pharmacology 2002;440(2-3):269-79.
2000: Baptist Gallwitz; T Ropeter; Corinna Morys-Wortmann; Rolf Mentlein; EG Siegel; Wolfgang E Schmidt
GLP-1-analogues resistant to degradation by dipeptidyl-peptidase IV in vitro.
Regulatory peptides 2000;86(1-3):103-11.
2000: EG Siegel; A Seidenstücker; Baptist Gallwitz; Frank Schmitz; A Reinecke-Lüthge; Günter Klöppel; Ulrich R Fölsch; Wolfgang E Schmidt
Insulin secretion defects in liver cirrhosis can be reversed by glucagon-like peptide-1.
The Journal of endocrinology 2000;164(1):13-9.
1999: EG Siegel; Baptist Gallwitz; Wolfgang E Schmidt; Ulrich R Fölsch
[Hepatogenic diabetes--the current concepts of its pathophysiology and therapy].
Deutsche medizinische Wochenschrift (1946) 1999;124(50):1530-5.
1999: Baptist Gallwitz; Wolfgang E Schmidt
[Inhibition of incretin degradation--a new therapy principle for treatment of type 2 diabetes?].
Zeitschrift für Gastroenterologie 1999;37(8):755-60.
1999: EG Siegel; G Scharf; Baptist Gallwitz; Rolf Mentlein; Corinna Morys-Wortmann; Ulrich R Fölsch; Wolfgang E Schmidt
Comparison of the effect of native glucagon-like peptide 1 and dipeptidyl peptidase IV-resistant analogues on insulin release from rat pancreatic islets.
European journal of clinical investigation 1999;29(7):610-4.
1999: EG Siegel; Baptist Gallwitz; G Scharf; Rolf Mentlein; Corinna Morys-Wortmann; Ulrich R Fölsch; Jürgen Schrezenmeir; K Drescher; Wolfgang E Schmidt
Biological activity of GLP-1-analogues with N-terminal modifications.
Regulatory peptides 1999;79(2-3):93-102.
1998: Baptist Gallwitz; Wolfgang E Schmidt
[Delay in diabetic late complications--a biological activity of insulin-C-peptide?].
Zeitschrift für Gastroenterologie 1998;36(10):925-8.
1998: EG Siegel; Baptist Gallwitz; Ulrich R Fölsch; Wolfgang E Schmidt
Effect of human pancreastatin peptide (hP-16) on oral glucose tolerance in man.
Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 1998;106(3):178-82.
1997: Baptist Gallwitz; Wolfgang E Schmidt
[Insulin analogs and new antidiabetic agents. Prospects in diabetes therapy].
Der Internist 1997;38(6):617-24; discussion 624.
1997: Baptist Gallwitz; Wolfgang E Schmidt
[The "diabetes" (db) gene of the mouse codes for a mutated leptin receptor--a cue to understanding obesity?].
Zeitschrift für Gastroenterologie 1997;35(4):307-10.
1996: Baptist Gallwitz; Wolfgang E Schmidt
[Glucagon-like peptide 1--a new physiologic mediator of satiety?].
Zeitschrift für Gastroenterologie 1996;34(11):775-7.
1996: Baptist Gallwitz; M Witt; Corinna Morys-Wortmann; U R Fölsch; Wolfgang E Schmidt
GLP-1/GIP chimeric peptides define the structural requirements for specific ligand-receptor interaction of GLP-1.
Regulatory peptides 1996;63(1):17-22.
1996: Baptist Gallwitz; Wolfgang E Schmidt
-Development of a mouse model for Helicobacter pylori infection in the human--progress toward vaccination against ulcer disease?-.
Zeitschrift für Gastroenterologie 1996;34(3):202-4.
1995: Baptist Gallwitz; R Günther; Wolfgang E Schmidt
[Selective increase of antiviral substances in the liver in hepatitis B by recombinant chylomicrons--a useful new therapeutic approach?].
Zeitschrift für Gastroenterologie 1995;33(12):725-6.
1994: Baptist Gallwitz; M Witt; G Paetzold; Corinna Morys-Wortmann; B Zimmermann; Klaus Eckart; U R Fölsch; Wolfgang E Schmidt
Structure/activity characterization of glucagon-like peptide-1.
European journal of biochemistry / FEBS 1994;225(3):1151-6.
1994: Baptist Gallwitz; U Jänig; U R Fölsch
[Differential diagnosis of granulomatous diseases--epithelioid cell granuloma in the intestine and liver in Crohn disease?].
Zeitschrift für Gastroenterologie 1994;32(5):252-5.
1993: Rolf Mentlein; Baptist Gallwitz; Wolfgang E Schmidt
Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum.
European journal of biochemistry / FEBS 1993;214(3):829-35.
1993: Baptist Gallwitz; M Witt; U R Fölsch; Werner Creutzfeldt; Wolfgang E Schmidt
Binding specificity and signal transduction of receptors for glucagon-like peptide-1(7-36)amide and gastric inhibitory polypeptide on RINm5F insulinoma cells.
Journal of molecular endocrinology 1993;10(3):259-68.
1991: Wolfgang E Schmidt; Hartmut Kratzin; Klaus Eckart; D Drevs; G Mundkowski; A Clemens; Stavros Katsoulis; Heiner Schäfer; Baptist Gallwitz; Werner Creutzfeldt
Isolation and primary structure of pituitary human galanin, a 30-residue nonamidated neuropeptide.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(24):11435-9.
1990: Baptist Gallwitz; Wolfgang E Schmidt; R Schwarzhoff; Werner Creutzfeldt
Galanin: structural requirements for binding and signal transduction in RINm5F insulinoma cells.
Biochemical and biophysical research communications 1990;172(1):268-75.
1990: Baptist Gallwitz; Wolfgang E Schmidt; J M Conlon; Werner Creutzfeldt
Glucagon-like peptide-1(7-36)amide: characterization of the domain responsible for binding to its receptor on rat insulinoma RINm5F cells.
Journal of molecular endocrinology 1990;5(1):33-9.
1988: Wolfgang E Schmidt; EG Siegel; R Lamberts; Baptist Gallwitz; Werner Creutzfeldt
Pancreastatin: molecular and immunocytochemical characterization of a novel peptide in porcine and human tissues.
Endocrinology 1988;123(3):1395-404.
1987: Wolfgang E Schmidt; EG Siegel; H Kümmel; Baptist Gallwitz; W Creutzfeldt
Commercially available preparations of porcine glucose-dependent insulinotropic polypeptide (GIP) contain a biologically inactive GIP-fragment and cholecystokinin-33/-39.
Endocrinology 1987;120(2):835-7.